Sulindac-d3

Sulindac-d3 is deuterium labeled Sulindac. Sulindac (MK-231) is a non-steroidal antiinflammatory agent, acts as a COX-2 inhibitor, and inhibits overexpression of COX-2.

Product Specifications

Product Name Alternative

MK-231-d3

UNSPSC

12352005

Hazard Statement

H301, H317, H334, H361

Target

Autophagy; COX; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Immunology/Inflammation; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Purity

99.4

Solubility

10 mM in DMSO

Smiles

OC(CC1=C(C)/C(C2=CC=C(F)C=C21)=C/C3=CC=C(C=C3)S(C([2H])([2H])[2H])=O)=O

Molecular Formula

C20H14D3FO3S

Molecular Weight

359.43

Precautions

H301, H317, H334, H361

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Boolbol SK, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996 Jun 1;56 (11) :2556-60.|[3]Cha BK, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7 (35) :57213-57227.|[4]Gong EY, et al. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells. Toxicol Lett. 2016 Sep 6;258:126-133.